Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Total Liabilities (2016 - 2025)

Avanos Medical's Total Liabilities history spans 12 years, with the latest figure at $426.5 million for Q3 2024.

  • For Q3 2024, Total Liabilities fell 15.18% year-over-year to $426.5 million; the TTM value through Sep 2024 reached $426.5 million, down 15.18%, while the annual FY2023 figure was $456.1 million, 7.99% down from the prior year.
  • Total Liabilities for Q3 2024 was $426.5 million at Avanos Medical, down from $435.8 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $2.0 billion in Q1 2020 and bottomed at $115.4 million in Q2 2022.
  • The 5-year median for Total Liabilities is $456.1 million (2023), against an average of $794.1 million.
  • The largest annual shift saw Total Liabilities tumbled 81.33% in 2021 before it skyrocketed 361.73% in 2022.
  • A 5-year view of Total Liabilities shows it stood at $410.7 million in 2020, then decreased by 18.92% to $333.0 million in 2021, then surged by 48.86% to $495.7 million in 2022, then decreased by 7.99% to $456.1 million in 2023, then dropped by 6.49% to $426.5 million in 2024.
  • Per Business Quant, the three most recent readings for AVNS's Total Liabilities are $426.5 million (Q3 2024), $435.8 million (Q2 2024), and $1.7 billion (Q1 2024).